Video Experimental Relacionado
Updated: Jan 8, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Adenocarcinoma de pulmón con inserción del exón 19 del EGFR identificado mediante un panel compacto y su respuesta a
Mika Horie1, Kazuhisa Nakashima1, Kojiro Hata1
1Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Abstract:
An 80-year-old man underwent a left lower lobectomy for lung adenocarcinoma. Next-generation sequencing in a clinical trial identified an epidermal growth factor receptor (EGFR) exon 19 insertion (exon19ins), which was not detected by the Oncomine™ Dx Target Test®, a companion diagnostic tool for EGFR mutations. However, the Lung Cancer Compact Panel® Dx (LCCP), another companion diagnostic tool, confirmed exon19ins. Osimertinib was administered, which led to a slight tumor response. This case suggests that LCCP may be useful in detecting rare EGFR mutations and that osimertinib may be effective against exon19ins.
